Fmr LLC Decreases Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Fmr LLC lessened its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 0.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,502,482 shares of the company’s stock after selling 3,393 shares during the period. Fmr LLC owned 16.67% of Apogee Therapeutics worth $440,696,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in APGE. Vanguard Group Inc. raised its stake in Apogee Therapeutics by 60.7% in the 1st quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after acquiring an additional 705,795 shares during the period. Point72 DIFC Ltd bought a new stake in shares of Apogee Therapeutics in the second quarter valued at approximately $660,000. XTX Topco Ltd purchased a new stake in shares of Apogee Therapeutics during the 2nd quarter valued at approximately $706,000. Victory Capital Management Inc. boosted its holdings in Apogee Therapeutics by 56.8% in the 2nd quarter. Victory Capital Management Inc. now owns 156,266 shares of the company’s stock worth $6,149,000 after buying an additional 56,607 shares during the period. Finally, Waypoint Capital Advisors LLC bought a new stake in Apogee Therapeutics during the 3rd quarter valued at $36,835,000. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Trading Up 1.0 %

Shares of NASDAQ APGE opened at $45.15 on Friday. The business has a 50-day moving average of $53.67 and a 200-day moving average of $48.51. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -18.80 and a beta of 2.93. Apogee Therapeutics, Inc. has a 12 month low of $17.17 and a 12 month high of $72.29.

Insiders Place Their Bets

In other news, insider Carl Dambkowski sold 6,665 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $59.12, for a total transaction of $394,034.80. Following the transaction, the insider now directly owns 267,463 shares in the company, valued at approximately $15,812,412.56. This represents a 2.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael Thomas Henderson sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $59.22, for a total value of $888,300.00. Following the completion of the sale, the chief executive officer now owns 1,339,487 shares of the company’s stock, valued at $79,324,420.14. The trade was a 1.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 114,995 shares of company stock valued at $6,128,295 in the last quarter. Corporate insiders own 36.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on APGE shares. Wedbush reaffirmed an “outperform” rating and issued a $87.00 price target on shares of Apogee Therapeutics in a report on Tuesday, November 12th. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Finally, Guggenheim raised their price objective on shares of Apogee Therapeutics from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $83.50.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.